secwatch.observer — SEC 8-K summary
======================================

Issuer:     MBX Biosciences, Inc. (MBX)
CIK:        0001776111
Form:       8-K
Filed at:   2026-08-06T12:03:59+00:00
Accession:  0001193125-26-336841
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MBX Biosciences Q2 net loss $37.1M; cash $418.6M; canvuparatide Phase 3 recruiting; MBX 4291 7% weight loss
--------------------------------------------------------------------------------

- Net loss of $37.1M for Q2 2026 vs $19.4M in Q2 2025; R&D expenses rose to $31.0M from $17.7M.
- Cash, cash equivalents and marketable securities of $418.6M as of June 30, 2026; expected to fund operations into 2029.
- Phase 3 oPTimize trial of once-weekly canvuparatide in hypoparathyroidism now recruiting; sites activated.
- MBX 4291 Phase 1 data: 7% mean weight loss at 8 weeks in first MAD cohort; 12-week MAD data on track for Q4 2026.
- Steve Hoerter appointed Chairman and CEO; John Smither appointed CFO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1776111/000119312526336841/0001193125-26-336841-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1776111/000119312526336841/mbx-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-336841

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer